 Home > Active Ingredient News > Study of Nervous System > NEJM: Efficacy of intranasal oxytocin treatment in children and adolescents with autism spectrum disorder

NEJM: Efficacy of intranasal oxytocin treatment in children and adolescents with autism spectrum disorder

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

spectrum payment arrangements

spectrum 110

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Experimental studies and small clinical trials have shown that intranasal oxytocin therapy can reduce social disorders in patients with autism spectrum disorders
.

Oxytocin has been used for many with autism spectrum disorders in clinical practice for children

child

Recently, a research article was published in the top medical journal NEJM.
Researchers performed a 24-week, placebo-controlled intranasal oxytocin treatment on children and adolescents aged 3 to 17 with autism spectrum disorder.
Phase 2 trial
.

Participants were randomly assigned at a ratio of 1:1, stratified according to age and language fluency, received oxytocin or placebo, administered intranasally, and the total target dose was 48 international units per day
.

The main outcome of the study was the least squares average change from the baseline of the Abnormal Behavior List Modified Social Withdrawal Scale (ABC-mSW), which included 13 items (scores range from 0 to 39, higher scores indicate less social interaction)

Of the 355 children and adolescents who were screened , 290 were included in the study
.

A total of 146 participants were assigned to the oxytocin group and 144 participants were assigned to the placebo group; 139 and 138 participants respectively completed the baseline and at least one post-baseline ABC-mSW assessment and were included in the improvement Analysis of intention to treat

Screening

It can be seen that this placebo-controlled trial of intranasal oxytocin treatment for children and adolescents with autism spectrum disorder showed that the least squares average change in social or cognitive function indicators compared with baseline over a 24-week period There is no significant difference between the groups compared
.

This placebo-controlled trial of intranasal oxytocin treatment in children and adolescents with autism spectrum disorder showed that the least squares average change in social or cognitive function indicators was not significant compared to baseline over a 24-week period The difference between groups
.

Original source:

Linmarie Sikich,et al.

Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder .
NEJM.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.